form_8-k.htm
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
_______________
Form 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported):
December
5, 2008
SCOLR
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-31982
|
|
91-1689591
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer Identification No.)
|
19204
North Creek Parkway, Suite 100
Bothell,
WA 98011
(Address
of principal executive offices)
(425) 368-1050
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
SCOLR
PHARMA, INC.
FORM
8-K
Item
5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers; Compensatory Arrangements of Certain
Officers.
(e) At a meeting
of the Board of Directors of SCOLR Pharma, Inc., a Delaware corporation (the
“Company”), held on December 5, 2008, a new compensation plan was approved upon
the recommendation of the Compensation Committee of the Board of Directors for
Daniel O. Wilds, Chief Executive Officer, Richard M. Levy, Chief Financial
Officer and Vice President of Finance, Alan M. Mitchel, Senior Vice President
and Chief Legal Officer, and Stephen J. Turner, Vice President, Chief Technical
Officer. Messrs. Wilds, Levy, Mitchel and Turner will not receive cash bonuses
for performance during 2008. In recognition of their contributions to the
Company’s success during 2008 Messrs. Levy, Mitchel and Turner received fully
vested stock options exercisable for a number of shares of the Company’s common
stock as set forth in the table below. While the
Compensation Committee recommended that the Board of Directors approve a grant
of options for Mr. Wilds based on performance during 2008, Mr. Wilds requested
that no options be awarded.
|
Richard
M. Levy
|
77,792
shares
|
|
Alan
M. Mitchel
|
115,397
shares
|
|
Stephen
J. Turner
|
86,706
shares
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
SCOLR Pharma,
Inc. |
|
| |
|
|
|
|
Dated:
December 11, 2008
|
By:
|
/s/
Daniel O. Wilds |
|
| |
|
Daniel
O. Wilds |
|
| |
|
President
and Chief Executive Officer |
|
| |
|
|
|